Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1810 results
May 2017
-
Media ReleaseNovartis data at ASCO, ICML and EHA meetings demonstrate meaningful advancements in cancer careUpdated analyses from the Kisqali® pivotal Phase III MONALEESA-2 trial in hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer to be…
-
Media ReleaseNovartis Foundation and partners launch initiative to tackle hypertension and its root causes in low-income urban communitiesBetter Hearts Better Cities is a Novartis Foundation initiative to improve cardiovascular health in low-income urban communities by addressing the prevention, management and control of hypertension…
-
Women in Science: Renee Rodgers
-
Novartis invites scrutiny of effort to improve access to medicine
Public health expert Richard Laing discusses how independent measurement of access programs can help ensure their success
-
In The NewsNovartis Access and government of Pakistan sign memorandum of understandingNovartis reaches agreement with Pakistan to increase access to medicines that address the rapid rise of chronic illness among poor people in the world's sixth most populous nation.
-
Media ReleaseNovartis celebrates 21st annual Community Partnership Day with over 24,500 associates volunteering in their local communitiesCommunity Partnership Day symbolizes the company's commitment to improving people's lives and serving our local communities Follow the excitement with #NovartisCPD2017 and #proudmoments2017 via…
-
In The NewsNovartis Access perspective: The key to fighting chronic disease in South-East Asia - young peopleHarald Nusser, Head of Novartis Social Business, explains why educating young people is key to fighting chronic disease in South-East Asia.
-
Taking clinical trials to the next level through technology
Learn how Novartis is using technology to improve the oncology clinical trial process.
-
Media ReleaseNovartis exercises exclusive option agreement with Conatus for the treatment of NASHExclusive license for emricasan supports rapidly growing development portfolio in chronic liver diseases, including NASH Conatus has initiated the Phase IIb ENCORE-LF clinical trial with…
-
In The NewsNovartis Access perspective: How smart partnerships can help us fight chronic disease in AfricaHarald Nusser, Head of Novartis Social Business, talks about how the pharmaceutical industry can work with partners to overcome access issues in poor countries.
April 2017
-
Media ReleaseNovartis receives FDA approval for Rydapt® in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocytosis (SM)Approval in newly diagnosed FLT3-mutated AML represents the first new treatment in more than 25 years[1],[2] Rydapt treatment regimen in FLT3-mutated AML demonstrated a significant improvement…
-
Media ReleaseAlcon announces EU launch of CyPass® Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucomaNow available in the UK, Germany, Italy and Spain, CyPass Micro-Stent is designed to significantly reduce intraocular pressure (IOP) CE indication has been expanded to allow patients to be…
Pagination
- ‹ Previous page
- 1
- …
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- …
- 151
- › Next page